New ARAMIS Phase III data to be presented at ASCO 2020: Nubeqa® (darolutamide) significantly improved overall survival with a favorable safety profile in men with non-metastatic prostate cancer

Liz Kane
Impactful Strategy

Suma Ramadas, PhD
Medical Affairs

Matt Turner
Patient Affordability

Matthew Durham
Omnidynamic Marketing

Joey Cohen
Medication Adherence

Frank Burrell
Scientific Storytelling

David Linetsky
Point-of-Care Marketing

Brenda Snow
Authentic Patient Voice

Bud Bilanich
Success Coach

Paul Theisen
Patient Acquisition

Amy Giles
Increasing Engagement

Stacey Gandler
Brand Nourishment

Daniel Sontupe
Market Access

Pat Purcell
Meeting Engagement